EDEN PRAIRIE, Minnesota, April 27, 2023 (GLOBE NEWSWIRE) — Miromatrix Medical Inc. (NASDAQ: MIRO) announces a new technology to bioengineer fully transplantable organs to save and improve the lives of patients. We announced today that we are a technology pioneering life sciences company. The company plans to report its first quarter 2023 results after the market close on Thursday, May 11, 2023. Our management will host a conference call at 3:30 pm Central Time / 4:30 pm Eastern Time.
Those wishing to listen to the conference call should call 877-407-3982 domestically or 201-493-6780 internationally. See Conference ID: 13738056. To listen to the live webcast, please visit the IR section of the Miromatrix website (https://miromatrix.gcs-web.com/).
Miromatrix is a life sciences company pioneering new technologies for bioengineering fully transplantable human organs to save and improve the lives of patients. Miromatrix has developed a proprietary perfusion technology platform for bioengineered organs that it believes can be efficiently scaled to address the shortage of available human organs. Miromatrix’s initial development focus is on human liver and kidney. For more information, please visit miromatrix.com.